Eikon Therapeutics, Inc. announced that it will issue 28,266,826 series B preferred shares at issue price of $17.688574 per share for the gross proceeds $499,999,843.446124 in funding on December 3, 2021. The shares are convertible, non-redeemable and non-cumulative. The shares carry non-cumulative dividend value of $0.06 per annum per share.

The shares will be convertible in common shares at a price of $17.688574 per share. The company will issue securities pursuant to exemption provided under Regulation D.